Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Transplantation Proceedings

• Publication date

  1995-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 7879049
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells.

  1995cited by this paper
• Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels.

  1993cited by this paper
• Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury.

  1993cited by this paper
• Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo.

  1993cited by this paper
• Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease.

  1991cited by this paper

• 40 Years of Percutaneous Coronary Intervention: History and Future Directions

  2018cites this paper
• P-Glycoprotein functional activity in peripheral blood lymphocytes. Role of immunosuppressants, pharmacogenomics and alloimmune response

  2013cites this paper
• Sirolimus and Cardiovascular Disease Risk in Liver Transplantation

  2013cites this paper
• Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

  2013cites this paper
• Krüppel‐like factor 4 is induced by rapamycin and mediates the anti‐proliferative effect of rapamycin in rat carotid arteries after balloon injury

  2012cites this paper
• Inhibitors of Mammalian Target of Rapamycin

  2012cites this paper
• Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment

  2011cites this paper
• Vascular smooth muscle cell proliferation in restenosis.

  2011cites this paper
• Results of 4-Year Analysis of Conversion from Calcineurin Inhibitors to mTOR Inhibitors in Renal Transplant Patients: Single-Center Experience

  2011cites this paper
• Basic Science for Clinicians Vascular Smooth Muscle Cell Proliferation in Restenosis

  2011cites this paper
• Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells.

  2010cites this paper
• Kathetergestützte, intrakoronare Applikation von Paclitaxel zur Restenoseprophylaxe: Durchführbarkeit und Sicherheit beim Menschen

  2009cites this paper
• Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.

  2009cites this paper
• Practical recommendations for the early use of m‐TOR inhibitors (sirolimus) in renal transplantation

  2009cites this paper
• The antichlamydial effects of drugs used in cardiovascular diseases

  2009cites this paper
• Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor

  2009cites this paper
• There is a choice for immunosuppressive drug nephrotoxicity: Is it time to change?

  2009cites this paper
• Calcineurin inhibitor-free protocols: risks and benefits.

  2007cites this paper
• Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin.

  2007cites this paper
• Anti-inflammatory drugs, sirolimus and inhibition of target of rapamycin and its effect on vascular diseases

  2007cites this paper
• Cell Cycle Approaches to the Treatment of In-Stent Restenosis

  2007cites this paper
• Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells.

  2007cites this paper
• Sirolimus, the first mTOR inhibitor.

  2006cites this paper
• Nebenwirkungen der Immunsuppression mit Sirolimus®, Cyc- losporin A und Kortison im Vergleich mit der Standard-Triple- Drug-Therapie nach Nierentransplantation

  2005cites this paper
• Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients.

  2005cites this paper
• Preventing restenosis in early drug‐eluting stent era: recent developments and future perspectives

  2004cites this paper
• Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia

  2004cites this paper
• The use of cyclosporine in renal transplantation.

  2004cites this paper
• Experience with everolimus.

  2004cites this paper
• Clinical impact of stent construction and design in percutaneous coronary intervention.

  2004cites this paper
• Sirólimus (2ª parte)

  2004cites this paper
• iNOS gene transfer for graft disease.

  2004cites this paper
• Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway.

  2004cites this paper
• Total recovery of heart grafts of non–heart-beating donors after 3 hours of hypothermic coronary oxygen persufflation preservation in an orthotopic pig transplantation model12

  2003cites this paper
• Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E‐Deficient Mice

  2003cites this paper
• Rapamycin in cardiovascular medicine

  2003cites this paper
• Rapamycin for Cardiac Transplant Rejection and Vasculopathy One Stone, Two Birds?

  2003cites this paper
• Sirolimus therapy in cardiac transplantation.

  2003cites this paper
• Immunosuppression and transplant vascular disease: benefits and adverse effects.

  2003cites this paper
• The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy

  2003cites this paper
• Sirolimus eluting stent: a new era in interventional cardiology?

  2003cites this paper
• Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat1

  2003cites this paper
• Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice.

  2003cites this paper
• Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients

  2003cites this paper
• Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy.

  2003cites this paper
• Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.

  2003cites this paper
• Rapamycin inhibits vascular remodeling in an experimental model of allograft vasculopathy and attenuates associated changes in fibrosis-associated gene expression.

  2003cites this paper
• The effect of novel immunosuppressants on extracellular matrix remodelling and the expression of fibrosis associated genes in an experimental model of allograft vasculopathy

  2003cites this paper
• CDKS and CKIS: Molecular targets for tissue remodelling

  2002cites this paper
• Sirolimus-based steroid-free maintenance immunosuppression.

  2002cites this paper
• Current practices: immunosuppression induction, maintenance, and rejection regimens in contemporary post-heart transplant patient treatment

  2002cites this paper
• From Beach to Bedside: History of the Development of Sirolimus

  2001cites this paper
• mTOR inhibitors: An overview

  2001cites this paper
• Potential therapeutic interventions to avoid or treat chronic allograft dysfunction.

  2001cites this paper
• Rapamycin in transplantation: a review of the evidence.

  2001cites this paper
• Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts.

  2001cites this paper
• Vascular and cellular mechanisms of chronic renal allograft dysfunction.

  2001cites this paper
• Fas Ligand Overexpression on Allograft Endothelium Inhibits Inflammatory Cell Infiltration and Transplant-Associated Intimal Hyperplasia1

  2001cites this paper
• Intimal Hyperplasia Infiltration and Transplant-Associated Endothelium Inhibits Inflammatory Cell Fas Ligand Overexpression on Allograft

  2001cites this paper
• Histopathology of chronic renal allograft dysfunction.

  2001cites this paper
• Molecular mechanisms of renal allograft fibrosis

  2001cites this paper
• Effect of p27 Deficiency and Rapamycin on Intimal Hyperplasia: In Vivo and In Vitro Studies Using a p27 Knockout Mouse Model

  2001cites this paper
• Bench to bedside: the development of rapamycin and its application to stent restenosis.

  2001cites this paper
• SIROLIMUS (RAPAMYCIN) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1

  2000cites this paper
• Maintenance immunosuppression: new agents and persistent dilemmas.

  2000cites this paper
• Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model.

  1999cites this paper
• Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.

  1999cites this paper
• Pharmacologic Immunosuppressants in Xenotransplantation

  1997cites this paper
• Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro.

  1996cites this paper
• Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.

  1996cites this paper
• [Immunosuppression in organ transplantation. New substances and therapeutic approaches].

  1996cites this paper
• Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis.

  1995cites this paper
• Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells.

  1995cites this paper